CagriSema Dual Pathway Metabolic Signaling Compound CagriSema combines two investigational molecules Cagrilintide (amylin analogue) and Semaglutide (GLP 1 receptor agonist), designed to influence key metabolic and appetite regulating pathways. Current ACC 2026: Meta analysis supports CagriSema as superior first line therapy in obesity Clinical Trials Arena Wegovy Cuts Food Noise, Cagrilintide Delivers Significant Weight Loss: Novo Nordisk Unveils New Data at EASD 2025 Clinical Trials Data on Novo Nordisk experimental weight loss drug show mostly mild side effects Reuters Novo Nosedives on Underwhelming CagriSema Phase III Weight Loss Data BioSpace Good looking results for Novo Nordisk's combo of GLP1ra semaglutide (known as #ozempic for #diabetes & #wegovy for obesity) + Cagrilintide (amylin agonist) to achieve #weightloss in obesity and obesity with type